Kamada Ltd. (NASDAQ:KMDA) to Issue Annual Dividend of $0.17

Kamada Ltd. (NASDAQ:KMDA) announced an annual dividend on Monday, August 17th. Shareholders of record on Thursday, August 27th will be paid a dividend of 0.17 per share by the biotechnology company on Thursday, September 17th. This represents a yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th.

Kamada has a dividend payout ratio of 46.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kamada to earn $0.60 per share next year, which means the company should continue to be able to cover its $0.18 annual dividend with an expected future payout ratio of 30.0%.

Kamada Stock Performance

Kamada stock opened at $7.76 on Tuesday. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The company has a market capitalization of $446.28 million, a price-to-earnings ratio of 20.42, a PEG ratio of 0.67 and a beta of 0.86. The stock has a fifty day moving average of $7.23 and a two-hundred day moving average of $7.95.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. On average, analysts forecast that Kamada will post 0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Kamada

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP grew its holdings in Kamada by 25.9% during the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 40,514 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Kamada by 43.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock valued at $1,183,000 after acquiring an additional 50,608 shares during the last quarter. Huntleigh Advisors Inc. increased its stake in Kamada by 5.5% during the fourth quarter. Huntleigh Advisors Inc. now owns 149,374 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 7,812 shares during the last quarter. Two Sigma Investments LP raised its stake in Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock worth $761,000 after acquiring an additional 4,504 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Kamada during the 1st quarter worth approximately $582,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.